MONTREAL (CANADA) AUGUST 22, 2019 – Inversago Pharma today announces that François Ravenelle, Founder and CEO, has been invited to share the company’s most recent results in a presentation entitled:
Safety Assessment in Non-Human Primates of New Cannabinoid-1 Receptor Blockers to Treat Hyperphagia, Obesity and Related Metabolic Disorders in PWS.
The 2019 PWS Research Symposium is organized by the Foundation for Prader-Willi Research.
